Kura Oncology, Inc. filings document a Nasdaq-listed biopharmaceutical company focused on precision medicines for cancer, including disclosures on KOMZIFTI™ (ziftomenib), acute myeloid leukemia programs, darlifarnib (KO-2806) and collaboration activity with Kyowa Kirin. Form 8-K reports cover financial results, FDA approval and product-launch disclosures, clinical program updates, milestone payments and other material events.
Governance filings include the company’s definitive proxy statement for annual meeting matters, director elections, auditor ratification and executive compensation. Other filings describe amendments to bylaws, the 2023 Inducement Option Plan, nonstatutory stock option grants and the company’s common stock listing on The Nasdaq Global Select Market.
Kura Oncology, Inc. reported third-quarter revenue of $22.839 million, versus $20.750 million a year earlier, including $13.922 million in KOMZIFTI product revenue and $8.917 million in collaboration revenue. Net loss was $70.215 million, versus $74.116 million. Nine-month revenue was $61.978 million and net loss was $211.875 million, versus $197.667 million.
Cash, cash equivalents and short-term investments totaled $492.1 million at September 30, 2026; nine-month operating cash use was $202.847 million. The ATM generated $31.5 million net from 2,563,568 shares sold at an average $12.64 per share. Following Caspian’s $50.0 million Series A financing, Kura retained about 49.2% of Caspian’s capital stock on an as-converted basis.
On November 9, 2026, Kura borrowed $50.0 million under a new loan and paid approximately $11.6 million to satisfy Hercules obligations; up to $225.0 million of additional borrowing is subject to tranche conditions. The loan matures November 9, 2033, with an 8.95% annual interest-rate cap. Single-digit royalties on U.S. net sales of ziftomenib and certain related products begin October 1, 2028. TPC Investments III LP purchased 687,758 shares for $5.0 million at $7.27 per share.
Kura Oncology, Inc. reported third-quarter 2026 results, including $13.9 million in KOMZIFTI net product revenue and a $70.2 million net loss. Product revenue rose 53% sequentially; new patient starts reached approximately 150, up 30%, and total prescriptions, including repeats, exceeded 420, up 65%. Total revenue was $22.839 million, compared with $20.750 million a year earlier.
Collaboration revenue was $8.9 million versus $20.8 million a year earlier. Cash, cash equivalents and short-term investments totaled $492.1 million as of September 30, 2026. Kura received $55 million at closing under an Oberland Capital agreement providing up to $300 million in potential funding, subject to applicable conditions. Each term loan has a seven-year term and bears 6.95% to 8.95% interest.
Kura updated 2026 collaboration revenue guidance to $40 million–$45 million and maintained $90 million–$110 million for each of 2027 and 2028; these amounts reflect non-cash accounting recognition, not cash-receipt timing. Kura reported FDA alignment on a planned single-arm darlifarnib monotherapy registrational study of approximately 40 patients, targeted to start in the first half of 2027. Based on its current operating plan, Kura expects resources to support operations beyond anticipated initial KOMET-017 topline results in 2028.
Kura Oncology, Inc. (KURA) is the issuer whose common stock is covered by BlackRock, Inc.'s ownership report. BlackRock reported beneficial ownership of 7,908,832 shares, or 8.9% of the class, as of September 30, 2026. It reported sole voting power over 7,763,592 shares and sole dispositive power over 7,908,832 shares, with no shared voting or dispositive power. The reported position reflects securities beneficially owned or deemed beneficially owned by certain BlackRock business units and affiliates, excluding any securities held by other business units whose beneficial ownership is disaggregated. BlackRock also stated that various persons may receive dividends or sale proceeds, but no one person's interest exceeds 5% of Kura's outstanding common shares.
Kura Oncology, Inc. Chief Legal Officer Teresa Brophy Bair sold 8,442 common shares at $10.4973 per share on September 28, 2026, leaving her with 187,002 shares held directly. The sale was reported as a sell-to-cover for taxes associated with vesting 1/6th of the shares underlying performance-based restricted stock units granted May 31, 2023. The transaction was reported under a Rule 10b5-1 trading plan.
Kura Oncology, Inc. Chief Operating Officer Kathleen Ford reported direct sales of 6,906 common shares on September 28, 2026, at $10.4973 per share and 3,668 shares on September 29 at a weighted-average $10.7516 per share. The September 28 sale was a sell-to-cover for taxes associated with vesting 1/6th of the underlying shares of performance-based restricted stock units; the September 29 shares were acquired upon vesting of performance restricted stock units on September 27. The sales were effected under a Rule 10b5-1 trading plan adopted May 29, 2026.
Kura Oncology, Inc.'s Chief Medical Officer, Mollie Leoni, reported direct sales of 12,448 common shares at $10.4973 per share on September 28, 2026, and 28,802 shares at a weighted average $10.7481 per share on September 29, 2026. The September 28 sale covered taxes tied to vesting one-sixth of the underlying performance-based restricted stock units after a development milestone was determined to have been met on September 27, 2026. The September 29 sale was made under a Rule 10b5-1 trading plan adopted on March 19, 2026; trades ranged from $10.53 to $10.89.
Kura Oncology, Inc. SVP, Finance & Accounting Thomas James Doyle sold 4,607 shares of common stock on September 28, 2026, at $10.4972 per share in a tax sell-to-cover tied to vesting of 1/6th of the underlying performance-based restricted stock units. After the sale, he directly held 142,428 shares; a separate indirect holding lists 500 shares through his spouse’s 401(k). The direct post-transaction total includes 1,868 shares acquired on May 17, 2026, under the Employee Stock Purchase Plan. No Rule 10b5-1 plan is reported.
Kura Oncology, Inc. Chief Commercial Officer Brian T. Powl reported selling 32,450 shares of common stock in three transactions on September 28 and 29, 2026. He sold 9,020 shares at $10.4973 per share on September 28 as a sell-to-cover for taxes associated with RSU vesting. He also sold 8,000 shares on September 28 at a weighted-average price of $10.5622 and 15,430 shares on September 29 at a weighted-average price of $10.7487. The latter two sales were made under a Rule 10b5-1 trading plan adopted May 22, 2026.
Kura Oncology, Inc. (KURA) Officer Brian Powl reported a proposed sale of 15,430 common shares, with an aggregate market value of $163,712.30 and an approximate sale date of September 29, 2026. The notice also lists prior sales during the past three months: 8,000 shares on September 28, 2026, 9,020 shares on September 27, 2026, and 4,345 shares on August 21, 2026.
Kura Oncology, Inc. (KURA) officer Mollie Vanessa Leoni gave notice of a proposed sale of 28,802 common shares, with an aggregate market value of $305,589.22 and an approximate sale date of September 29, 2026, through Morgan Stanley Smith Barney LLC. The securities detail identifies performance stock units from the issuer dated September 27, 2026. Leoni also reported selling 12,448 common shares during the preceding three months, with an aggregate market value of $130,670.01.